2023 Fiscal Year Final Research Report
Development of innovative personalized treatment using cancer-derived exosomes for disseminated gastric cancer
| Project/Area Number |
21K16414
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | エクソソーム / 胃癌 / 腹膜播種 / 悪液質 / 患者由来モデル / PDX |
|---|
| Outline of Final Research Achievements |
Using a cancer cell line, we attempted to show enhancement of gastric cancer therapeutic effect by encapsulating existing anti-cancer drugs into cancer-derived exosomes, but did not achieve the expected results. We have revised our research course and reported the quantification and utility of immune-related sPD-L1 as a blood molecule in gastric cancer-induced cachexia (weight loss and chronic inflammation). Focusing on changes in cancer-derived exosome inclusions, especially microRNAs, in a cancer-specific hypoxic environment, we performed and reported functional analysis on microRNA 185, which acts in a tumor suppressive manner. In addition, we established several mouse models using surgically harvested cancer tissues from patients, and in one model of small intestine cancer, we were able to establish a cell line that can be cultured for a long period of time, which we reported in the paper.
|
| Free Research Field |
腫瘍外科学
|
| Academic Significance and Societal Importance of the Research Achievements |
胃癌治療効果改善のために、癌悪液質の克服に向けた分子機構についての知見を得た。また患者由来モデルを樹立し、今後の個別化治療研究に資する研究基盤を樹立した。エクソソーム自体の特定の環境下（低酸素）での変化を解析し得たことで、他の腫瘍微小環境にも応用可能な解析系を確立した。当初の研究目的の直接的な解明は行えなかったが、これらの結果は胃癌に対する患者由来の腫瘍由来エクソソーム解析と治療応用を今後進めていく基盤となり、社会的学術的意義を有するものと考えている。
|
